Onco-Innovations Limited has announced promising results from its licensed technology of PNKP inhibitors, which enhance the ...

("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (CDE) of the National ...

Onco-Innovations’ licensed technology demonstrates promise to enhance chemotherapy effectiveness by overcoming cancer cell resistance: Vancouver, BC Saturday, February 1, 2025, ...

The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...

and Investigation of Isomerically Hydroxylated Indenoisoquinoline Analogues as Topoisomerase I Poisons Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell ...

The Phase I trial will evaluate the safety and efficacy of the company’s drug which targets tumours whilst leaving normal ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

These drugs are subdivided into specific classes such as alkylating agents, antimetabolites, anthracyclines and topoisomerase inhibitors. Targeting Ceramide Transfer Protein (CERT) is known to ...

IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion molecule that is overexpressed in several types of solid tumors ...